Home›Mirtazapine›Mirtazapine + Nitrazepam

Does Mirtazapine Interact with Nitrazepam?

The mirtazapine label warns that benzodiazepines can add to impairment of cognitive and motor skills. Nitrazepam is not individually named in this label; the evidence presented here is the benzodiazepine-class statement.

Label evidence and limitations

Class-level label evidence. The label advises avoiding concomitant use with benzodiazepines. The specific nitrazepam mapping and individual treatment implications need clinical assessment; this is not a directly named pair in the source.

Product scope: Oral mirtazapine tablets; class-level benzodiazepine warning.

Read the DailyMed label: These highlights do not include all the information needed to use MIRTAZAPINE TABLETS safely and effectively. See full prescribing information for MIRTAZAPINE TABLETS. MIRTAZAPINE tablets, for oral use Initial U.S. approval: 1996
Section: 7 Drug Interactions — Benzodiazepines and Alcohol. Compared version 3, label date 2023-06-29. The linked label may be updated after this comparison.

This comparison uses the label identifier saved with the CDI record. The compared version may be newer than the original extraction.

AI-assisted source comparison dated 2026-10-16. This is a comparison of label text, not independent clinical review or an individual safety assessment. CDI's stored severity category is not an FDA-assigned rating. Confirm your exact medicines and formulations with your pharmacist or prescriber before changing treatment.

Stored CDI classification
Moderate
Management
Confirm exact products with your pharmacist
Data Source
Product label via NLM DailyMed

What To Tell Your Doctor or Pharmacist

If you are taking Mirtazapine and your doctor is considering prescribing Nitrazepam (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Never stop or change either medication without first consulting your healthcare provider
💊 Mirtazapine(Remeron)+💊 Nitrazepam

Severity & Interaction Details

🟡
Stored CDI classification: moderate
Class-level label evidence
The label advises avoiding concomitant use with benzodiazepines. The specific nitrazepam mapping and individual treatment implications need clinical assessment; this is not a directly named pair in the source.
Stored CDI scale
MinorContra
On record
Yes
Drug A class
—
Drug B class
—
Source
NLP:mirtazapine

How to interpret this source comparison

The label advises avoiding concomitant use with benzodiazepines. The specific nitrazepam mapping and individual treatment implications need clinical assessment; this is not a directly named pair in the source.

About Mirtazapine and Nitrazepam

Mirtazapine is also sold under the brand name Remeron. Mirtazapine additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:mirtazapine

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Mirtazapine and Nitrazepam against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations